学术周报 · IF≥10 或专科旗舰刊
胆胰外科领域文献阅读汇编
2026年第45周 (2026-11-06) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer letters | 3 | IF 11.8 |
| Pharmacological research | 3 | IF 12.2 |
| Annals of surgery | 3 | IF 7.4 |
| Nature | 2 | IF 56.1 |
| Cancer discovery | 2 | IF 29.5 |
| Advanced healthcare materials | 1 | IF 11.0 |
| Journal of the American Chemical Society | 1 | IF 16.6 |
| Immunity | 1 | IF 30.6 |
| JAMA surgery | 1 | IF 15.6 |
| Signal transduction and targeted therapy | 1 | IF 81.2 |
1胰腺癌 (15篇)
临床研究 (5篇)
Gemcitabine resistance remains a major therapeutic barrier in pancreatic ductal adenocarcinoma (PDAC), for which median survival in advanced disease has remained near one year despite extensive clinical investigation. Using artificial intelligence (AI)-guided structure-based drug repurposing, we identified sitagliptin, a DPP-4 inhibitor for diabetes, as a candidate ribonucleotide reductase (RRM1/2) inhibitor that sensitizes PDAC to gemcitabine. Molecular dynamics simulations suggested that sitagliptin disrupts gemcitabine-RRM1/2 interactions, downregulating RRM1/2 expression and restoring chemosensitivity across PDAC cell lines, patient-derived organoids, and mouse models. Sitagliptin enhanced the anti-tumor efficacy of both gemcitabine-nab-paclitaxel (GnP) and FOLFIRINOX regimens in preclinical studies. We conducted SITGEM-CARE, a single-center phase 2 trial in 22 patients with locally advanced or metastatic PDAC (median age 65.0 years; ECOG performance status 1, 86.4%; Stage IV, 68.2%; liver metastases, 54.5%). Patients received sitagliptin 100 mg orally once daily continuously, plus gemcitabine 1000 mg/m² and nab-paclitaxel 125 mg/m² on days 1 and 8 of 21-day cycles. Among 22 evaluable patients, eight achieved a partial response, and 11 had stable disease, yielding an objective response rate of 36.4% (95% CI: 17.2-59.3%) and a disease control rate of 86.4% (95% CI: 65.1-97.1%), with tumor shrinkage in 86.4% of patients. At a median follow-up of 9.9 months, the median progression-free survival was 6.6 months (95% CI: 4.8-12.4) with 6-month and 9-month PFS rates of 63.6% and 43.5%, respectively. Median overall survival was 12.5 months (95% CI: 7.8-not reached), with 62.9% of patients alive at 12 months. Furthermore, treatment was well tolerated, with no Grade 4/5 treatment-related adverse events. These findings are hypothesis-generating and warrant confirmation in adequately powered, randomized trials. ClinicalTrials.gov: NCT05947825.
中文摘要:吉西他滨耐药仍是胰腺导管腺癌(PDAC)的主要治疗障碍,晚期患者的中位生存期尽管经过大量临床研究仍接近一年。我们利用人工智能(AI)引导的基于结构的药物重定位,发现糖尿病用药DPP-4抑制剂西格列汀是候选的核糖核苷酸还原酶(RRM1/2)抑制剂,可使PDAC对吉西他滨敏感。分子动力学模拟提示西格列汀干扰吉西他滨与RRM1/2的相互作用,在PDAC细胞系、患者来源类器官和小鼠模型中下调RRM1/2表达并恢复化疗敏感性。临床前研究中,西格列汀增强了吉西他滨联合白蛋白结合型紫杉醇(GnP)和FOLFIRINOX方案的抗肿瘤疗效。我们开展了SITGEM-CARE单中心2期试验,纳入22例局部晚期或转移性PDAC患者(中位年龄65.0岁;ECOG体能状态1分者86.4%;IV期68.2%;肝转移54.5%)。患者持续每日口服西格列汀100 mg,并在21天周期的第1天和第8天接受吉西他滨1000 mg/m²和白蛋白结合型紫杉醇125 mg/m²。22例可评估患者中,8例达到部分缓解,11例为疾病稳定,客观缓解率为36.4%(95% CI:17.2-59.3%),疾病控制率为86.4%(95% CI:65.1-97.1%),86.4%的患者出现肿瘤缩小。中位随访9.9个月时,中位无进展生存期为6.6个月(95% CI:4.8-12.4),6个月和9个月无进展生存率分别为63.6%和43.5%。中位总生存期为12.5个月(95% CI:7.8-未达到),12个月时62.9%的患者存活。治疗耐受性良好,未发生4/5级治疗相关不良事件。这些结果具有产生假设的性质,需要在样本量充足的随机试验中确认。ClinicalTrials.gov:NCT05947825。
Exercise induces a variety of changes in the tumor microenvironment, with beneficial effects in several tumor types. However, a better understanding of the clinical effects of exercise and mediating mechanisms is needed to maximize the utility of exercise for patients. In this study, we analyzed tumors from patients with pancreatic ductal adenocarcinoma (PDAC) in the PancFit trial and identified an exercise-induced reduction in cells expressing α-smooth muscle actin (αSMA). Interrogation of changes in tumor stromal composition with exercise in a murine PDAC model revealed a microbially influenced reduction in αSMA+ cells and Il6-expressing inflammatory cancer-associated fibroblasts (iCAF). Cholic acid, a microbial bile acid, was increased in both patients and murine models with exercise, as a potential mediator of exercise-induced reduction in iCAFs. Consistent with these findings, patients that exercised more also exhibited fewer iCAFs and lower tumor IL6 expression, supporting a stromal remodeling effect of physical activity. In summary, this study demonstrates that the antitumor effect of exercise includes stromal remodeling, which is affected by microbial metabolites. Exercise-induced changes in cancer-associated fibroblasts vary with microbiome composition, which may explain the heterogeneity in tumor responses to exercise and could guide future exercise trials in cancer patients.
中文摘要:运动可改变肿瘤微环境,并在多种肿瘤中产生有益作用。要充分发挥运动对患者的效用,仍需更好理解运动的临床效应及中介机制。本研究分析PancFit试验中胰腺导管腺癌(PDAC)患者的肿瘤,发现运动使表达α-平滑肌肌动蛋白(αSMA)的细胞减少。在小鼠PDAC模型中考察运动对肿瘤间质组成的影响,观察到αSMA+细胞及表达Il6的炎症性癌相关成纤维细胞(iCAF)出现受微生物影响的减少。一种微生物胆汁酸——胆酸,在运动后的患者和小鼠模型中均升高,可能是运动诱导iCAF减少的潜在介导物。与这些发现一致,运动更多的患者iCAF也更少,肿瘤IL6表达更低,支持体力活动具有间质重塑作用。该研究显示运动的抗肿瘤作用包括间质重塑,并受微生物代谢物影响。运动诱导的癌相关成纤维细胞变化随微生物组组成而异,这可能解释肿瘤对运动反应的异质性,并可为未来癌症患者的运动试验提供指导。
Eileen M. O'Reilly, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, NY, whose research focuses on therapies for pancreas cancer, spoke with Cancer Discovery's Suzanne Rose about daraxonrasib combinations, treatment strategies under development, the need for genomic testing, and what big headlines might come in pancreas cancer.
中文摘要:Eileen M. O'Reilly,医学博士,纽约纪念斯隆凯特琳癌症中心的肿瘤内科医生,其研究聚焦于胰腺癌的治疗。她与《Cancer Discovery》的Suzanne Rose交谈,内容涉及daraxonrasib的联合用药、正在研发中的治疗策略、基因组检测的必要性,以及胰腺癌领域可能出现的重大新闻。
Pancreatic ductal adenocarcinoma (PDAC) is a near-universally lethal malignancy, with KRAS mutations driving tumorigenesis in over 90% of cases. For decades considered undruggable, oncogenic KRAS has now been therapeutically engaged across multiple mutational subtypes, a revolution precipitated by allele-specific covalent inhibitors and accelerated by the emergence of RAS(ON) multi-selective inhibitors. The pivotal phase 3 RASolute 302 trial of daraxonrasib, a pan-RAS(ON) inhibitor, demonstrated nearly doubled median overall survival (13.2 versus 6.7 months; HR 0.40; P < 0.0001) over standard chemotherapy in previously treated metastatic PDAC. Concurrently, mutation-selective G12D inhibitors (zoldonrasib, VS-7375, INCB161734), G12D-targeted protein degraders (setidegrasib), G12C-selective RAS(ON) compounds (elironrasib), and next-generation MEK inhibitors (atebimetinib) are advancing through clinical evaluation. This review synthesizes the biological basis of KRAS-driven oncogenesis in the pancreas, the mutational landscape and its prognostic implications, the structural and mechanistic evolution of KRAS inhibitor classes, contemporary and emerging clinical data from recent trials, toxicity profiles and their management, and resistance mechanisms. The field stands at an inflection point: daraxonrasib now redefines second-line PDAC management, while first-line combination regimens with daraxonrasib plus chemotherapy have produced an ORR of 58% in early-phase single-arm data, a result now being tested in the randomized RASolute 303 trial. The challenge ahead lies in translating these results into durable remissions through rational combination therapy and in overcoming acquired resistance.
中文摘要:胰腺导管腺癌(PDAC)是几乎普遍致命的恶性肿瘤,超过90%的病例由KRAS突变驱动肿瘤发生。数十年来被认为不可成药,而致癌KRAS如今已在多种突变亚型上实现治疗性干预,这一转变由等位基因特异性共价抑制剂引发,并因RAS(ON)多选择性抑制剂的问世而加速。泛RAS(ON)抑制剂daraxonrasib的关键3期RASolute 302试验显示,在既往接受过治疗的转移性PDAC中,其中位总生存期较标准化疗近乎翻倍(13.2个月对6.7个月;HR 0.40;P < 0.0001)。同时,突变选择性G12D抑制剂(zoldonrasib、VS-7375、INCB161734)、靶向G12D的蛋白降解剂(setidegrasib)、G12C选择性RAS(ON)化合物(elironrasib)以及新一代MEK抑制剂(atebimetinib)正推进临床评价。本综述整合了KRAS驱动胰腺致癌作用的生物学基础、突变图谱及其预后意义、KRAS抑制剂类别在结构与机制上的演进、近期试验的当代与新兴临床数据、毒性特征及其管理,以及耐药机制。该领域正处于转折点:daraxonrasib已重新定义PDAC二线治疗,而daraxonrasib联合化疗的一线方案在早期单臂数据中客观缓解率达58%,该结果正在随机对照的RASolute 303试验中接受检验。未来的挑战在于通过合理的联合治疗把这些结果转化为持久缓解,并克服获得性耐药。
Early diagnosis and accurate staging are essential for improving treatment efficacy and clinical outcomes of pancreatic cancer (PC), but remain challenging because of limited early PC-specific biomarkers and high-performance detection methods. In this paper, we developed a machine learning (ML)-enhanced terahertz (THz)-colorimetric dual-mode metadevice based on metallic nanonetworks for multiplexed microRNA (miRNA) detection and early PC diagnosis. Clinical sample measurements and bioinformatics analysis identified miRNA-21, miRNA-1290, and miRNA-320a as candidate PC biomarkers. Target miRNAs triggered the assembly of DNA-functionalized Fe and Au nanoparticles (NPs) with PEI-modified CuS NPs into ternary Fe/Au/Cu nanonetworks, generating THz and colorimetric signals through their dielectric and peroxidase-like properties. This target-triggered assembly enabled three-miRNA panel analysis without enzyme-mediated nucleic acid amplification and achieved attomolar-level miRNA profiling. Six ML algorithms were integrated to develop predictive models for PC diagnosis and staging. Linear discriminant analysis (LDA) achieved diagnostic accuracies of 97.8% (95% CI: 88.2-99.9%) in the training cohort (n = 45) and 96.7% (95% CI: 82.8-99.9%) in the validation cohort (n = 30), with 100% sensitivity for early PC in both cohorts. Compared with CA19-9, CA125, and CEA, the multiplexed miRNA-based dual-mode metadevice showed higher efficacy (area under the curve, AUC: 1.00 vs 0.905), supporting its potential for clinical miRNA-based liquid biopsy.
中文摘要:早期诊断和准确分期对提高胰腺癌(PC)治疗效果和临床结局至关重要,但早期PC特异性生物标志物有限且高性能检测方法不足,使这一目标仍具挑战。本文开发了基于金属纳米网络的机器学习(ML)增强太赫兹(THz)-比色双模式超材料器件,用于多重microRNA(miRNA)检测和早期PC诊断。临床样本检测和生物信息学分析确定miRNA-21、miRNA-1290和miRNA-320a为候选PC生物标志物。靶miRNA触发DNA功能化Fe和Au纳米颗粒(NPs)与PEI修饰CuS NPs组装成三元Fe/Au/Cu纳米网络,借助其介电特性和类过氧化物酶特性产生THz和比色信号。这种靶标触发的组装无需酶介导的核酸扩增即可实现三-miRNA组合分析,并达到阿摩尔级miRNA谱分析。整合六种ML算法构建PC诊断和分期预测模型。线性判别分析(LDA)在训练队列(n=45)中诊断准确率为97.8%(95% CI:88.2-99.9%),在验证队列(n=30)中为96.7%(95% CI:82.8-99.9%),两个队列对早期PC的敏感性均为100%。与CA19-9、CA125和CEA相比,基于多重miRNA的双模式超材料器件表现出更高效能(曲线下面积,AUC:1.00 vs 0.905),支持其用于临床基于miRNA液体活检的潜力。
基础研究 (10篇)
Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a novel risk factor for pancreatic cancer, particularly early liver metastasis. However, the underlying mechanisms and effective therapeutic strategies remain largely unclear. Here, based on clinical databases, patient tissue samples, and single-cell sequencing of mouse models, we identified CD44 as a key contributor to MAFLD-associated pancreatic cancer progression. High CD44 expression was significantly associated with poor survival in patients with pancreatic cancer and was further elevated in MAFLD-associated liver metastatic lesions. Considering that the limited effects of single treatment, we developed a cationic DOTAP/cholesterol liposomal nanoplatform co-loaded with gemcitabine, IR780, and CD44 siRNA (GIR@Lip) for combined chemotherapy, photothermal therapy, and immunotherapy. GIR@Lip nanoparticles exhibited excellent size uniformity, stability, and photothermal conversion efficiency, which could efficiently inhibit KPC cells' viability, migration and invasion, downregulate CD44 expression and stimulate immune response. Furthermore, GIR@Lip efficiently accumulated in tumor tissues in vivo, exhibiting a significant reduction in liver metastatic lesions and remodeling the M1 type tumor associated macrophages (TAMs), CD4+ and CD8+ T cells. Collectively, these findings identify CD44 as a potential therapeutic target for MAFLD-associated pancreatic cancer liver metastasis and highlight GIR@Lip as a promising multimodal strategy for its treatment.
中文摘要:代谢功能障碍相关脂肪性肝病(MAFLD)已成为胰腺癌的新风险因素,尤其与早期肝转移相关。其机制和有效治疗策略仍不清楚。研究基于临床数据库、患者组织样本和小鼠模型的单细胞测序,发现CD44是MAFLD相关胰腺癌进展的关键促进因子。CD44高表达与胰腺癌患者生存不良显著相关,并在MAFLD相关肝转移灶中进一步升高。鉴于单一治疗效果有限,构建了阳离子DOTAP/胆固醇脂质体纳米平台,共载吉西他滨、IR780和CD44 siRNA(GIR@Lip),用于化疗、光热治疗和免疫治疗联合。GIR@Lip纳米颗粒具有良好粒径均一性、稳定性和光热转换效率,可有效抑制KPC细胞活力、迁移和侵袭,下调CD44表达并激发免疫应答。GIR@Lip在体内有效蓄积于肿瘤组织,显著减少肝转移灶,并重塑M1型肿瘤相关巨噬细胞(TAMs)、CD4+和CD8+ T细胞。这些结果确定CD44是MAFLD相关胰腺癌肝转移的潜在治疗靶点,并表明GIR@Lip是有前景的多模式治疗策略。
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest human cancers, driven in 90% of cases by KRAS mutations and characterized by an intense desmoplastic reaction, early metastasis, and therapy resistance. The mechanisms driving PDAC initiation, however, remain poorly understood because early acinar transformation is difficult to model in a controlled microenvironment. Here, we introduce a microvalve-bioprinted 3D pancreatic cancer initiation niche that supports culture of primary acini from wild-type and Kras-mutant mice, up to 14 days, within gelatin-methacryloyl (GelMA) hydrogels. Our printing strategy enables tuning of hydrogel stiffness to cover the range reported for healthy murine pancreas and early stages of desmoplastic remodelling. In this system, wild-type acini retain a predominantly acinar phenotype, whereas intermediate GelMA conditions cooperate with pre-existing oncogenic Kras to promote acinar-to-ductal metaplasia and proliferative programs associated with early neoplastic reprogramming. Multimodal readouts revealed a stiffness-permissive window in which mechanical cues cooperated with oncogenic Kras to promote acinar transdifferenciation, proliferation and distinct stiffness-dependent secretory programs, including inflammatory and stromal-associated factors with previously reported relevance to PDAC biology. The deterministic droplet geometry supported reproducible, high-throughput, and longitudinal analysis under conditions inaccessible to conventional extrusion or laser‑assisted bioprinting, providing an experimental framework to study early Kras-driven acinar reprogramming.
中文摘要:胰腺导管腺癌(PDAC)仍是最致命的人类癌症之一,90%病例由KRAS突变驱动,以强烈促结缔组织增生反应、早期转移和治疗耐药为特征。PDAC起始机制仍不清楚,因为早期腺泡转化难以在受控微环境中建模。我们引入微阀生物打印的3D胰腺癌起始微生态位,可在明胶甲基丙烯酰基(GelMA)水凝胶中培养野生型和Kras突变小鼠的原代腺泡长达14天。打印策略可调节水凝胶刚度,覆盖健康小鼠胰腺及促结缔组织增生重塑早期报道的范围。在该系统中,野生型腺泡主要保持腺泡表型,而中等GelMA条件与既有致癌Kras协同,促进腺泡-导管化生及与早期肿瘤性重编程相关的增殖程序。多模态读数揭示一个刚度许可窗口,机械线索与致癌Kras协同促进腺泡转分化、增殖及不同的刚度依赖性分泌程序,包括炎症和基质相关因子,这些因子先前报道与PDAC生物学相关。确定性液滴几何结构支持在传统挤出或激光辅助生物打印难以实现的条件下进行可重复、高通量及纵向分析,为研究早期Kras驱动的腺泡重编程提供实验框架。
Controlling the delivery of chemotherapy to the tumor site is a long-standing goal of the medical field, as it could not only enhance the anticancer activity of the treatment but also reduce damage to the rest of the body. The emergence of bioorthogonal catalysis as a strategy capable of mediating continuous drug production in a nonenzymatic fashion has created the opportunity to develop so-called "bioorthogonal therapies," which aim to generate the anticancer agents inside the tumors. Herein, we describe a novel class of supramolecular materials comprising ultrathin palladium nanosheets and fluorenylmethoxycarbonyl-diphenylalanine that self-assemble in water to form injectable, self-healing, biocompatible catalytic gels that convert inactive prodyes and prodrugs into active small molecules. The relatively weak physicochemical cross-links generated by the hybrid metal-peptide fibers facilitate the flow of the gel under mild shear stress (shear-thinning), thereby enabling precise intratumoral injections in vivo and localized prodrug activation. The strategy was validated in an aggressive pancreatic cancer xenograft model in mice, setting out a new direction for the field of bioorthogonal therapies.
中文摘要:控制化疗药物向肿瘤部位递送是医学领域长期追求的目标,它既能增强治疗的抗癌活性,也能减少对全身其他部位的损伤。生物正交催化能够以非酶方式持续生成药物,这一策略的出现为发展「生物正交疗法」创造了机会,目标是在肿瘤内部生成抗癌药物。本文描述一类新型超分子材料,由超薄钯纳米片与芴甲氧羰基-二苯丙氨酸组成,可在水中自组装形成可注射、自愈合、生物相容的催化凝胶,将无活性前体染料和前药转化为活性小分子。金属-肽杂化纤维形成的物理化学交联相对较弱,使凝胶在温和剪切应力下流动(剪切变稀),从而能够在体内进行精准瘤内注射并实现局部前药活化。该策略在小鼠侵袭性胰腺癌异种移植模型中得到了验证,为生物正交疗法领域指出了新方向。
KRAS is the most frequently mutated oncogene in pancreatic cancer, with over 90% of patients harboring KRAS mutations, approximately 45% of which are G12D substitutions. The development of KRASG12D selective inhibitors, such as HRS-4642, MRTX1133 and RMC-9805, has brought new hope for treating this patient population. However, the clinical efficacy of these inhibitors is limited by the emergence of acquired resistance, the mechanisms of which remain incompletely understood. Our study employed a KRAS saturation mutagenesis library to systematically map the landscape of KRAS mutations conferring resistance to HRS-4642 and MRTX1133. We identified several secondary mutations-including R73P, E63P, D69W, and M72K-that confer resistance to both inhibitors, while M72H was found specifically resistant to HRS-4642. We further characterized the impact of these mutations on KRAS downstream signaling and performed structural modeling of the mutant proteins. Through molecular dynamics simulations, we suggested that the R73P mutation, although distant from the binding pocket, is predicted to exert a global dynamic effect on the allosteric site, thereby disrupting inhibitor-protein interactions. This suggests the existence of a novel class of KRAS resistance mutations and a previously unrecognized mechanism of acquired resistance to KRAS-targeted therapies. Furthermore, we identified Y64W, A59G, and R73P as mutations that concurrently confer resistance to the tri-complex inhibitor RMC-9805, as well as to the allosteric inhibitors MRTX1133 and HRS-4642. This comprehensive analysis delineates the global landscape of secondary resistance mutations to KRASG12D-selective inhibitors.
中文摘要:KRAS是胰腺癌中最常见的突变癌基因,超过90%的患者携带KRAS突变,其中约45%为G12D替换。HRS-4642、MRTX1133和RMC-9805等KRASG12D选择性抑制剂的开发为治疗这一患者群体带来新希望。然而,这些抑制剂的临床疗效受获得性耐药出现的限制,其机制仍不完全清楚。采用KRAS饱和突变文库,系统绘制赋予HRS-4642和MRTX1133耐药性的KRAS突变图谱。鉴定出若干二次突变,包括R73P、E63P、D69W和M72K,它们对两种抑制剂均产生耐药,而M72H仅对HRS-4642耐药。进一步表征这些突变对KRAS下游信号的影响,并对突变蛋白进行结构建模。通过分子动力学模拟,提示R73P突变虽远离结合口袋,但预计对变构位点产生整体动态效应,从而破坏抑制剂与蛋白的相互作用。这提示存在一类新的KRAS耐药突变,以及一种此前未识别的KRAS靶向治疗获得性耐药机制。同时,鉴定出Y64W、A59G和R73P同时赋予对三复合物抑制剂RMC-9805以及变构抑制剂MRTX1133和HRS-4642的耐药性。该综合分析描绘了KRASG12D选择性抑制剂二次耐药突变的整体图谱。
Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
中文摘要:目前已有多种靶向RAS的策略可用于治疗胰腺癌。胰腺癌前病变同样携带KRAS突变,这些工具在癌症拦截方面具有很大潜力。
Claudins (CLDNs), as major components of tight junctions in epithelial cells, are emerging as attractive non-mutant targets for controlling the growth and metastasis of various cancers. However, the mechanisms by which CLDNs modulate tumor progression remain largely unclear. Here, we unexpectedly found that CLDN12 is expressed in cancer-associated fibroblasts (CAFs), which are generally not considered tight junction-forming cells. CLDN12 expression in fibroblasts increased their motility and, importantly, promoted direct adhesion to pancreatic cancer cells through homophilic CLDN12-CLDN12 interactions. This CLDN12-dependent physical interaction between fibroblasts and tumor cells markedly enhanced cancer cell invasion. Moreover, TGF-β produced by cancer cells further induced the upregulation of CLDN12 expression in fibroblasts. In vivo, CLDN12-positive fibroblasts facilitated distant metastasis of pancreatic cancer to liver and diaphragm. Targeting CLDN12 with the synthetic peptide C12-pm efficiently decreased the liver metastasis of pancreatic cancer. Taken together, these findings reveal a previously unrecognized role of CLDN12-expressing fibroblasts in promoting pancreatic cancer metastasis through direct physical interactions with tumor cells and highlight CLDN12-mediated interactions as a potential therapeutic target for metastatic pancreatic cancer.
中文摘要:紧密连接蛋白(CLDN)是上皮细胞紧密连接的主要成分,正成为控制多种癌症生长和转移的有吸引力的非突变靶点。CLDN调节肿瘤进展的机制仍很不清楚。我们意外发现CLDN12在癌症相关成纤维细胞(CAF)中表达,而这类细胞通常不被认为形成紧密连接。成纤维细胞中的CLDN12表达提高了其运动能力,并通过同型CLDN12-CLDN12相互作用促进其与胰腺癌细胞直接黏附。这种依赖CLDN12的成纤维细胞与肿瘤细胞之间的物理相互作用显著增强了癌细胞侵袭。癌细胞产生的TGF-β进一步诱导成纤维细胞中CLDN12表达上调。在体内,CLDN12阳性成纤维细胞促进胰腺癌向肝和膈肌的远处转移。用合成肽C12-pm靶向CLDN12有效减少了胰腺癌的肝转移。这些发现揭示了表达CLDN12的成纤维细胞通过与肿瘤细胞直接物理相互作用促进胰腺癌转移这一此前未被认识的作用,并表明CLDN12介导的相互作用可作为转移性胰腺癌的潜在治疗靶点。
The liver is the primary site of metastasis in pancreatic ductal adenocarcinoma (PDAC), and liver metastases are a major cause of mortality1,2. Nutrient availability in the metastatic niche influences colonization efficiency; however, the metabolic heterogeneity of disseminated tumour cells can also reshape the local microenvironment3-5. Loss of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in de novo serine biosynthesis, is observed in nearly 40% of PDACs, and renders these cells dependent on exogenous serine (exSer)6. Although a neuron-tumour metabolic cross-talk supports exSer-dependent PDAC cells at the primary site6, it remains unclear how these cells adapt to the metastatic liver niche. Here we show that exSer-dependent PDAC cells reprogram neighbouring hepatocytes through a CXCL5-CXCR2 axis. Activation of CXCR2 in hepatocytes promotes PI3K-AKT signalling, leading to the sequestration of FOXO3A in the cytoplasm and derepression of PHGDH transcription, thereby enhancing serine production in hepatocytes. This hepatocyte-derived serine supports the outgrowth of exSer-dependent PDAC liver metastases. Accordingly, genetic or pharmacological inhibition of individual nodes within the CXCL5-CXCR2-PI3K-AKT-FOXO3A axis, or hepatocyte-specific deletion of Phgdh or Cxcr2, markedly reduces the liver-metastasis burden in mice and prolongs survival, particularly when dietary serine is restricted. Our findings reveal a cancer cell-hepatocyte metabolic cross-talk and identify therapeutic targets for exSer-dependent PDAC liver metastases.
中文摘要:肝脏是胰腺导管腺癌(PDAC)转移的主要部位,肝转移是患者死亡的主要原因之一。转移龛中的营养可用性影响定植效率;播散肿瘤细胞的代谢异质性也能重塑局部微环境。近40%的PDAC中观察到丝氨酸从头合成限速酶磷酸甘油酸脱氢酶(PHGDH)缺失,使这些细胞依赖外源性丝氨酸(exSer)。尽管神经-肿瘤代谢交互在原发部位支持依赖exSer的PDAC细胞,这些细胞如何适应肝转移龛仍不清楚。依赖exSer的PDAC细胞通过CXCL5-CXCR2轴重编程邻近肝细胞。肝细胞中CXCR2激活促进PI3K-AKT信号,使FOXO3A滞留于细胞质并解除对PHGDH转录的抑制,从而增强肝细胞的丝氨酸生成。肝细胞来源的丝氨酸支持依赖exSer的PDAC肝转移灶生长。据此,遗传或药理抑制CXCL5-CXCR2-PI3K-AKT-FOXO3A轴中的任一节点,或肝细胞特异性敲除Phgdh或Cxcr2,均可显著降低小鼠肝转移负荷并延长生存,尤其在限制膳食丝氨酸时。研究结果揭示癌细胞与肝细胞之间的代谢交互,并确定依赖exSer的PDAC肝转移的治疗靶点。
Immunogenic cell death (ICD) is a robust strategy to reprogram immunologically "cold" pancreatic ductal adenocarcinoma (PDAC) into "hot" tumors and augment immunotherapeutic efficacy, yet clinically viable ICD-inducing regimens and their regulatory mechanisms remain elusive. Here, we sought to develop an optimized combinatorial therapy for ICD induction in PDAC and decipher its core molecular pathway. Spatial transcriptomics of human PDAC tissues revealed that elevated ICD activity in cancer lesions correlates strongly with favorable patient prognosis. In vitro and in vivo functional assays demonstrated that co-treatment with elesclomol‑CuCl₂ (ES‑CU, a potent cuproptosis inducer) and oxaliplatin (L‑OHP) synergistically suppresses PDAC cell proliferation, migration and invasion, while triggering robust reactive oxygen species (ROS)-dependent ICD. Mechanistically, this regimen inhibits calreticulin (CALR) palmitoylation at Cys137, abrogating CALR degradation via the autophagy‑lysosome pathway and facilitating its ER-to-membrane translocation to initiate ICD signaling. This potent ICD response promotes dendritic cell maturation and enhances CD8⁺T cell-mediated cytotoxicity through the TLR4/NF‑κB axis, which single-cell RNA sequencing of clinical PDAC samples supported in neoadjuvant therapy responders. Collectively, our findings identify CALR palmitoylation inhibition as a key driver of L‑OHP/ES‑CU-induced ICD, reshaping the tumor immune microenvironment to provide a promising chemo-immunotherapeutic strategy for PDAC.
中文摘要:免疫原性细胞死亡(ICD)是将免疫「冷」胰腺导管腺癌(PDAC)重编程为「热」肿瘤并增强免疫治疗疗效的有力策略,但临床可行的ICD诱导方案及其调控机制仍不明确。我们试图为PDAC的ICD诱导开发优化的联合治疗策略,并解析其核心分子通路。人PDAC组织的空间转录组显示,癌灶中ICD活性升高与患者预后良好密切相关。体外和体内功能实验表明,elesclomol-CuCl₂(ES-CU,一种强效铜死亡诱导剂)与奥沙利铂(L-OHP)联合处理可协同抑制PDAC细胞增殖、迁移和侵袭,同时触发强烈的活性氧(ROS)依赖性ICD。机制上,该方案抑制钙网蛋白(CALR)Cys137位点的棕榈酰化,阻断CALR经自噬-溶酶体途径的降解,并促进其从内质网向细胞膜转位,从而启动ICD信号。该强效ICD反应通过TLR4/NF-κB轴促进树突状细胞成熟,并增强CD8阳性T细胞介导的细胞毒性;临床PDAC样本的单细胞RNA测序在新辅助治疗应答者中支持这一发现。这些结果共同表明,抑制CALR棕榈酰化是L-OHP/ES-CU诱导ICD的关键驱动因素,可重塑肿瘤免疫微环境,为PDAC提供有前景的化学免疫治疗策略。
Lipocalin 2 (LCN2) is upregulated in many cancers, including pancreatic ductal adenocarcinoma (PDAC), and contributes to tumor development. LCN2 regulates microbial composition, which can influence PDAC outcomes, and has been implicated in ferroptosis resistance in several cancer types. However, the role of tumor-derived LCN2 in mediating ferroptosis and the tumor microbiome in PDAC remains unclear. Here, we show that human PDAC tumors with high LCN2 expression have altered expression of genes involved in ferroptosis, oxidative stress responses, and microbial regulation. Loss of LCN2 in PDAC cells dysregulates ferroptosis-associated pathways, increases lipid peroxidation, and sensitizes cells to ferroptosis induction. In orthotopic PDAC models, the ferroptosis inducer imidazole ketone erastin (IKE) promoted tumor growth in Lcn2-expressing tumors, whereas this effect was absent in tumors lacking LCN2. In addition, tumor-derived Lcn2 expression and ferroptosis induction were associated with distinct changes in the pancreatic tumor microbiome. Overall, these findings identify tumor-derived LCN2 as an important modulator of ferroptotic stress responses in PDAC and suggest that inhibition of tumor-derived LCN2 may enhance susceptibility to ferroptosis-based therapeutic strategies.
中文摘要:脂质运载蛋白2(LCN2)在包括胰腺导管腺癌(PDAC)在内的多种癌症中上调,并促进肿瘤发展。LCN2调节微生物组成,而后者可影响PDAC结局;LCN2还在多种癌症中与铁死亡抵抗有关。肿瘤来源的LCN2在PDAC中介导铁死亡和影响肿瘤微生物组的作用仍不清楚。我们发现,LCN2高表达的人PDAC肿瘤中,参与铁死亡、氧化应激反应和微生物调控的基因表达发生改变。PDAC细胞缺失LCN2后,铁死亡相关通路失调,脂质过氧化增加,细胞对铁死亡诱导更敏感。在原位PDAC模型中,铁死亡诱导剂咪唑酮埃拉斯汀(IKE)促进表达Lcn2的肿瘤生长,而缺乏LCN2的肿瘤中未出现该效应。肿瘤来源的Lcn2表达和铁死亡诱导与胰腺肿瘤微生物组的不同变化相关。这些发现表明,肿瘤来源的LCN2是PDAC铁死亡应激反应的重要调节因子,抑制肿瘤来源的LCN2可能提高基于铁死亡的治疗策略的敏感性。
In pancreatic ductal adenocarcinoma (PDAC), the fibroblastic stroma constitutes most of the tumor mass and is remarkably devoid of functional blood vessels, leaving unresolved how PDAC cells obtain essential metabolites and water-insoluble lipids. We find that cancer-associated fibroblasts (CAFs) acquire and transfer lipids from blood-borne particles to PDAC cells through trogocytosis of CAF plasma membranes, a process requiring the CAF-expressed phospholipid scramblase anoctamin 6 (ANO6) to promote PDAC cell survival. Cancer cells and CAFs form synapse-like contacts that induce cytosolic calcium influx in CAFs through Orai channels, activating ANO6 and driving phosphatidylserine exposure on CAF membranes, which initiates trogocytosis and transfer of membrane lipids, including cholesterol, to PDAC cells. This ANO6-dependent phosphatidylserine externalization also supports CAF-mediated immunosuppression of cytotoxic T cells through trogocytosis. Blockade of ANO6 antagonizes tumor growth, partly by disrupting cholesterol delivery to cancer cells, and attenuates immune suppression, identifying ANO6 as a candidate therapeutic target in PDAC.
中文摘要:在胰腺导管腺癌(PDAC)中,成纤维细胞性间质构成肿瘤主体的大部分,且显著缺乏功能性血管,PDAC细胞如何获得必需代谢物和水不溶性脂质一直未明。我们发现,癌相关成纤维细胞(CAF)通过其质膜的胞啃作用,从血液来源颗粒获取脂质并转移给PDAC细胞;该过程需要CAF表达的磷脂爬行酶anoctamin 6(ANO6)来促进PDAC细胞存活。癌细胞与CAF形成突触样接触,经Orai通道诱导CAF胞质钙内流,激活ANO6并促使CAF膜上磷脂酰丝氨酸外露,从而启动胞啃并将包括胆固醇在内的膜脂转移至PDAC细胞。这种依赖ANO6的磷脂酰丝氨酸外露还通过胞啃支持CAF介导的对细胞毒性T细胞的免疫抑制。阻断ANO6可拮抗肿瘤生长,部分通过破坏向癌细胞输送胆固醇实现,并减弱免疫抑制,提示ANO6是PDAC的候选治疗靶点。
2胰腺癌外科 (3篇)
基础研究 (3篇)
Ribosomal frameshifting, an uncommon translational recoding event, is best known for its regulatory roles in viral gene expression1,2, whereas its physiological relevance in mammals remains poorly understood. Here we show that specific codon pairs trigger efficient -1 frameshifting preferentially in cancer cells. Mechanistically, this recoding arises from ribosomal pausing associated with tRNA and amino acid availability, and is amplified by impaired ribosome quality control and sustained phosphorylation of ribosomal protein S6. We found that this codon-pair-specific frameshifting represents an intrinsic state of translational dysregulation, which is prevalent across cancer cells and reshapes protein synthesis. Taking advantage of this frameshifting-permissive state in cancer cells, we engineered a frameshifting-activated synthetic therapeutic circuit (FAST) that conditionally expresses the pyroptotic effector gasdermin D. FAST is activated across diverse cancer cell types, inducing potent and selective pyroptosis, while sparing normal tissues from detectable toxicity. As a proof of concept, systemic AAV9-mediated delivery of FAST in mouse models of colorectal and pancreatic cancer elicited pronounced tumour regression, robust immune activation and synergistic effects with immune checkpoint blockade. Collectively, these findings reveal codon-pair-dependent ribosomal frameshifting as a feature of translational dysregulation in cancer cells and establish translation-coupled gene circuits as a strategy for cancer-selective therapy.
中文摘要:核糖体移码是一种不常见的翻译重编码事件,人们最熟知的是它在病毒基因表达中的调控作用,但其在哺乳动物中的生理意义仍不清楚。我们发现特定密码子对会优先在癌细胞中触发高效的-1移码。机制上,这种重编码源于与tRNA和氨基酸可用性相关的核糖体停滞,并因核糖体质量控制受损和核糖体蛋白S6持续磷酸化而放大。这种密码子对特异性移码代表一种内在的翻译失调状态,在癌细胞中普遍存在并重塑蛋白质合成。利用癌细胞中这种允许移码的状态,我们构建了移码激活的合成治疗回路FAST,条件性表达焦亡效应分子gasdermin D。FAST在多种癌细胞类型中被激活,诱导强效且选择性的焦亡,同时正常组织未出现可检测的毒性。作为概念验证,在结直肠癌和胰腺癌小鼠模型中经AAV9系统递送FAST引起明显肿瘤消退、强烈免疫激活,并与免疫检查点阻断产生协同效应。这些发现揭示密码子对依赖性核糖体移码是癌细胞翻译失调的一个特征,并确立翻译偶联基因回路作为癌症选择性治疗的策略。
Tertiary lymphoid structures (TLSs) in tumors are associated with improved responses to immunotherapy. Here, we examined the impact of type 1 conventional dendritic cells (cDC1s) in TLS formation. Reprogrammed tumor cells into cDC1-like cells remodeled the tumor microenvironment and induced immunogenic TLSs (imgTLSs) across melanoma, colon, bladder, breast, and pancreatic cancer models with distinct genetic backgrounds. cDC1-like cells activated lymphotoxin, TNF, and interferon programs and engaged early with T cells through MHC class I and CD40 signaling to induce imgTLSs containing BCL6+ germinal centers, independently of endogenous cDC1s. Intratumoral positioning shaped distinct cDC1-like cell states, with DC-LAMP+ CCR7+ migratory cDC1s nucleating niches enriched in CD4+, CD8+ T cells, and B cells in mouse and human tumors. ImgTLSs sustained B and T cell responses and promoted systemic immunity through expansion of shared clonotypes in distant, untreated tumors. Our findings outline the spatial organization, signaling programs and interactions of cDC1-like cells that initiate intratumoral lymphoid structures and establish cellular reprogramming as a strategy toward overcoming resistance to immunotherapy.
中文摘要:肿瘤中的三级淋巴结构(TLSs)与免疫治疗应答改善相关。我们考察了1型经典树突状细胞(cDC1s)在TLS形成中的作用。将肿瘤细胞重编程为cDC1样细胞可重塑肿瘤微环境,并在黑色素瘤、结肠癌、膀胱癌、乳腺癌和胰腺癌等遗传背景不同的模型中诱导免疫原性TLS(imgTLSs)。cDC1样细胞激活淋巴毒素、TNF和干扰素程序,并通过MHC I类和CD40信号与T细胞早期相互作用,从而诱导含BCL6+生发中心的imgTLSs,且不依赖内源性cDC1s。瘤内定位塑造了不同的cDC1样细胞状态,DC-LAMP+ CCR7+迁移性cDC1s在小鼠和人类肿瘤中形成富含CD4+、CD8+ T细胞和B细胞的微环境。imgTLSs维持B细胞和T细胞应答,并通过在远处未治疗肿瘤中扩增共享克隆型促进系统性免疫。这些发现勾勒出启动瘤内淋巴结构的cDC1样细胞的空间组织、信号程序和相互作用,并将细胞重编程确立为克服免疫治疗耐药的策略。
RAS proteins (HRAS, KRAS, NRAS) contribute to many physiological signal transduction pathways involving cell growth, cell division, and survival. RAS proteins possess GTPase activity. These proteins toggle between inactive and active forms; the conversion of inactive RAS-GDP to active RAS-GTP is facilitated by guanine nucleotide exchange factors (GEFs) turning the switch on and the intrinsic RAS-GTPase activity accelerated by the GTPase activating proteins (GAPs) turning the switch off. RAS is the upstream component of the RAS-RAF-MEK-ERK and the PI3-kinase-AKT signaling cascades. One-fifth of all cancers bear RAS mutations and about 75% of them involve KRAS. Except for the GTP/GDP binding site, RAS proteins lack deep surface pockets able to bind high-affinity inhibitors, which impeded the development of specific antagonists. KRAS mutations occur frequently in pancreatic, lung, and colorectal cancers, which are among the deadliest cancers worldwide. RAS mutations include those of codon 12 G12D/V/C/R, codon 13 G13D, and codon 61 Q61R/K/L. Studies conducted over the last 15 years led to the discovery of the so-called RAS switch II pocket. Sotorasib and adagrasib, which interact with this pocket and directly block the action of KRAS following the covalent modification of KRAS C12, are FDA-approved for the second-line treatment of KRASG12C-mutant non-small cell lung cancer. Daraxonrasib, which is an indirect inhibitor of wildtype and mutant H/K/NRAS isoforms, is FDA approved for the second-line treatment of all RAS-mutant pancreatic cancers. Daraxonrasib first forms a complex with cyclophilin A (a chaperone protein), which then interacts with active RAS to block RAS signaling.
中文摘要:RAS蛋白(HRAS、KRAS、NRAS)参与许多涉及细胞生长、细胞分裂和存活的生理信号转导通路。RAS蛋白具有GTP酶活性。这些蛋白在失活型与活性型之间切换;鸟苷酸交换因子(GEF)促使失活的RAS-GDP转为活性的RAS-GTP,使开关开启,而GTP酶激活蛋白(GAP)加速RAS固有的GTP酶活性,使开关关闭。RAS是RAS-RAF-MEK-ERK和PI3激酶-AKT信号级联的上游组分。所有癌症中约五分之一携带RAS突变,其中约75%涉及KRAS。除GTP/GDP结合位点外,RAS蛋白缺乏能够结合高亲和力抑制剂的深表面口袋,这阻碍了特异性拮抗剂的开发。KRAS突变常见于胰腺癌、肺癌和结直肠癌,这些癌症属于全球最致命的癌症。RAS突变包括12位密码子的G12D/V/C/R、13位密码子的G13D和61位密码子的Q61R/K/L。过去15年的研究发现了所谓的RAS开关II口袋。Sotorasib和adagrasib与该口袋结合,并在KRAS C12共价修饰后直接阻断KRAS的作用,已获FDA批准用于KRASG12C突变非小细胞肺癌的二线治疗。Daraxonrasib是野生型及突变型H/K/NRAS亚型的间接抑制剂,已获FDA批准用于所有RAS突变胰腺癌的二线治疗。Daraxonrasib先与亲环素A(一种伴侣蛋白)形成复合物,该复合物再与活性RAS相互作用,阻断RAS信号传导。
3胆管癌/胆道手术 (3篇)
临床研究 (1篇)
To investigate the impact of VEGFA and EGF genetic polymorphisms on postoperative survival, susceptibility, transcriptomics, and systemic proteomic regulation in cholangiocarcinoma (CCA). Angiogenesis and growth factor signaling via vascular endothelial growth factor A (VEGFA) and epidermal growth factor (EGF) are key drivers of CCA biology, yet the clinical relevance of their genetic variants remains poorly defined. A cohort of 221 patients undergoing curative-intent CCA resection at Charité-Berlin was analyzed. Patients were genotyped for 6 angiogenesis-related SNPs, including VEGFA rs3025039 and EGF rs4444903, and survival associations were assessed using Cox regression. The prognostic relevance of intratumoral VEGFA and EGF mRNA expression and pathway co-expression was evaluated in an independent transcriptomic cohort. Population-level associations with CCA susceptibility and serum proteomics were analyzed in the UK Biobank (n>500,000). The VEGFA rs3025039 T allele was associated with improved cancer-specific survival, particularly in intrahepatic CCA, while the EGF rs4444903 G allele was linked to improved survival in perihilar CCA. High intratumoral VEGFA or EGF expression correlated with poorer survival in external validation, but this association was lost for EGF after multivariable adjustment. VEGFA -high tumors showed increased proliferative and suppressed immune transcriptional signatures, whereas EGF -high tumors displayed limited changes. UK Biobank analysis revealed increased intrahepatic CCA susceptibility among VEGFA T allele carriers, while the EGF G allele was associated with elevated circulating EGF levels. VEGFA and EGF polymorphisms exert distinct effects on CCA, influencing disease susceptibility, postoperative outcomes, and systemic signaling, supporting their potential as biomarkers for clinical stratification.
中文摘要:探讨VEGFA与EGF基因多态性对胆管癌(CCA)术后生存、易感性、转录组及全身蛋白质组调控的影响。VEGFA介导的血管生成和EGF介导的生长因子信号是CCA生物学的关键驱动因素,但其遗传变异的临床意义仍不明确。研究分析柏林夏里特医院221例接受根治性CCA切除的患者队列,对6个血管生成相关SNP进行基因分型,包括VEGFA rs3025039和EGF rs4444903,并用Cox回归评估生存关联。另在独立转录组队列中评价瘤内VEGFA与EGF mRNA表达及通路共表达的预后意义。在UK Biobank(n>500,000)中分析人群层面与CCA易感性的关联及血清蛋白质组。VEGFA rs3025039 T等位基因与癌症特异性生存改善相关,尤其在肝内CCA中;EGF rs4444903 G等位基因与肝门部CCA生存改善相关。外部验证中,瘤内VEGFA或EGF高表达与较差生存相关,但EGF在多变量校正后该关联消失。VEGFA高表达肿瘤呈增殖相关转录特征增强、免疫相关特征受抑,EGF高表达肿瘤变化有限。UK Biobank分析显示,VEGFA T等位基因携带者肝内CCA易感性升高,EGF G等位基因与循环EGF水平升高相关。VEGFA与EGF多态性对CCA产生不同影响,涉及疾病易感性、术后结局和全身信号传导,支持其作为临床分层生物标志物的潜力。
基础研究 (2篇)
Cholangiocarcinomas (CCAs) are cancers that arise in the peripheral or central bile ducts. They have substantial heterogeneity in their etiologies and histopathologic phenotypes, ranging from cholangiolar carcinomas arising from the smallest bile ducts or from dedifferentiating hepatocytes through cellular plasticity, to ductular cancers in medium and large-sized bile ducts. The surgical delineation of intrahepatic, perihilar, and distal CCAs does not match the biological classification, as intrahepatic CCAs include both small duct cholangiolar carcinoma and intermediate duct ductular or mucinous CCAs, which have different genomic and genetic characteristics. Despite their overall poor prognosis, CCAs have proven to include the most actionable target-rich types of cancer, with intrahepatic CCAs including relatively high percentages of fibroblast growth factor receptor 2 fusions and isocitrate dehydrogenase 1 or 2 mutations, as well as other currently or potentially targetable aberrations. We discuss the etiologies and risk factors for CCAs, review the pathophysiologic basis for tumor molecular heterogeneity in CCA, and discuss the known links with mutational signatures in subgroups of CCA, such as oxidative stress, aging, and exogenous exposures. The potential roles of differences in cell type-specific replication timing and immunoselective and metabolic pressures are discussed, as are the implications of synergistic or antagonistic oncogenic effects, leading to unique patterns of co-occurrence vs mutual exclusivity of alterations. In addition, we review the impacts of common genetic variants and known pathogenic germline or somatic variants that predispose carriers to CCA. Finally, we discuss the role of epigenetics and variations in DNA methylation in heterogeneity of CCA within the context of evolving treatment options and remaining key gaps in knowledge.
中文摘要:胆管癌(CCA)发生于外周或中心胆管,其病因与组织病理表型高度异质,既包括起源于最小胆管、或经细胞可塑性由去分化肝细胞形成的小胆管癌,也包括发生于中大胆管的胆管型癌。肝内、肝门周围与远端胆管癌的手术学划分与生物学分类并不一致,肝内CCA同时包含小胆管型胆管癌与中间胆管型胆管型或黏液型CCA,二者基因组与遗传学特征不同。尽管总体预后差,CCA被证明属于可靶向靶点最丰富的癌种之一,肝内CCA中成纤维细胞生长因子受体2融合与异柠檬酸脱氢酶1或2突变占相对较高比例,还存在其他当前或潜在可靶向的异常。文章讨论CCA的病因和危险因素,回顾肿瘤分子异质性的病理生理基础,并讨论CCA亚组中与突变特征相关的已知联系,如氧化应激、衰老和外源性暴露。细胞类型特异性复制时序差异、免疫选择与代谢压力可能发挥的作用得到讨论,协同或拮抗性致癌效应导致改变共现与互斥的独特模式,其意义也得到讨论。文章还回顾常见遗传变异及已知使携带者易感CCA的致病性胚系或体细胞变异的影响。在治疗选择不断演变及关键知识缺口仍存在的背景下,文章讨论表观遗传学和DNA甲基化变化在CCA异质性中的作用。
Intrahepatic cholangiocarcinoma (ICC) is notoriously resistant to treatment, largely due to a "cold" microenvironment shaped by the Warburg effect. This metabolic signature leads to excessive lactate buildup, which acts as a physical and chemical shield against T-cell infiltration. To breach this barrier, we developed ultrasound-activated GdMnO3 (GMO) perovskite nanozymes that forcibly reverse the Warburg effect by accelerating the lactate-to-pyruvate metabolic switch. Through Gd-incorporating, we optimized the Mn-based electronic structure to achieve high-efficiency lactate catabolism, which is pulsed by ultrasound to maximize enzymatic turnover. This intervention does not merely deplete lactate; it reshapes the tumor's "bioenergetic engine" from glycolytic acidification toward mitochondrial oxidation. When cloaked in M1 macrophage membranes (GMO@M), these nanozymes selectively accumulate in ICC tissues. The subsequent Mn2+ release triggers the cGAS-STING pathway, synergizing with the metabolic shift to flip the immunological status of the tumor. Combined with αPD-L1, this ultrasound-driven metabolic recalibration yields potent systemic immunity and durable tumor regression. Our findings demonstrate that targeting the Warburg effect via responsive nanozymes is a decisive strategy for sensitizing recalcitrant ICC to immunotherapy.
中文摘要:肝内胆管癌(ICC)以治疗抵抗著称,很大程度上源于瓦伯格效应塑造的「冷」微环境。这种代谢特征导致乳酸过度积聚,形成阻挡T细胞浸润的物理和化学屏障。为突破这一屏障,我们开发了超声激活的GdMnO3(GMO)钙钛矿纳米酶,通过加速乳酸向丙酮酸的代谢转换来强制逆转瓦伯格效应。通过引入Gd,我们优化了锰基电子结构以实现高效乳酸分解代谢,并用超声脉冲激发以最大化酶周转。这一干预不仅消耗乳酸,还将肿瘤的「生物能量引擎」从糖酵解酸化重塑为线粒体氧化。用M1巨噬细胞膜包裹后(GMO@M),这些纳米酶选择性聚集于ICC组织。随后释放的Mn2+触发cGAS-STING通路,与代谢转变协同,翻转肿瘤的免疫状态。与αPD-L1联合,这种超声驱动的代谢重校准产生强效全身免疫和持久肿瘤消退。我们的发现表明,通过响应性纳米酶靶向瓦伯格效应,是使难治性ICC对免疫治疗敏感的决定性策略。
4肝切除/肝癌手术 (2篇)
临床研究 (1篇)
Portal vein embolization (PVE) is routinely used before major hepatectomy to induce hypertrophy of the future liver remnant (FLR) and reduce post-hepatectomy liver failure. Conventional PVE relies on permanent embolic agents, resulting in irreversible portal occlusion, which may be associated with complications and may limit subsequent therapeutic options in patients who do not ultimately undergo resection. Whether transient portal deprivation alone can induce clinically relevant liver regeneration remains unknown. We evaluated the efficacy and safety of temporary selective PVE using an absorbable gelatin agent. EMBORES was a multicenter prospective single-arm phase II trial conducted in six French hepatobiliary centers. Between May 3, 2018, and May 3, 2021, adult patients requiring major hepatectomy and preoperative PVE were included. Selective portal branches were embolized using powdered absorbable gelatin sponge. The primary endpoint was FLR hypertrophy assessed by computed tomography (CT) volumetry 4-6 weeks after PVE. Secondary endpoints included feasibility, morbidity, portal vein recanalization, and surgical outcomes. This trial is registered with ClinicalTrials.gov, NCT02945059. 34 patients were enrolled and 32 underwent temporary PVE. Mean age was 63.4 years (standard deviation [SD] 8.9), and colorectal liver metastases accounted for 18 (56%) of 32 indications. Technical success was achieved in all patients. One major complication occurred (1 [3.1%] of 32 patients), while liver function remained preserved. Complete and partial portal vein recanalization were observed in 17 (53%) and 9 (28%) of 32 patients, respectively. Mean FLR volume increased from 580 (SD 169) mL to 690 (SD 188) mL, corresponding to a mean hypertrophy ratio of 9.5% (SD 10.2). Five patients required repeat embolization using a permanent agent because of insufficient hypertrophy. Overall, 23 (71.8%) of 32 patients underwent major hepatectomy, with no postoperative mortality. Temporary PVE using an absorbable embolic agent is feasible, safe, and capable of inducing clinically meaningful liver hypertrophy before major hepatectomy, supporting the concept that transient portal vein occlusion may be sufficient to stimulate liver regeneration in selected patients. The EMBORES study was funded by the French Ministry of Health through a national hospital clinical research program grant awarded in 2015 (Programme Hospitalier de Recherche Clinique National, PHRC-15-15-0201).
中文摘要:大范围肝切除术前常规行门静脉栓塞(PVE),以诱导残余肝(FLR)肥大、降低肝切除后肝衰竭风险。传统PVE使用永久性栓塞材料,造成门静脉不可逆闭塞,可能带来并发症,也会限制最终未接受切除患者的后续治疗选择。单纯短暂阻断门静脉血流能否诱导具有临床意义的肝再生,此前并不清楚。本研究评估以可吸收明胶材料行临时选择性PVE的有效性与安全性。EMBORES为多中心、前瞻性、单臂II期试验,在法国六家肝胆中心开展。2018年5月3日至2021年5月3日纳入需行大范围肝切除且术前需PVE的成年患者,以粉末状可吸收明胶海绵栓塞选择性门静脉分支。主要终点为PVE后4至6周经CT体积测量评估的FLR肥大程度;次要终点包括可行性、并发症、门静脉再通及手术结局。试验注册号ClinicalTrials.gov NCT02945059。共入组34例患者,其中32例接受临时PVE。平均年龄63.4岁(标准差8.9),结直肠癌肝转移占适应证的18/32(56%)。全部患者均获技术成功。出现1例重大并发症(1/32,3.1%),肝功能保持稳定。32例中完全再通17例(53%)、部分再通9例(28%)。FLR平均体积由580 mL(标准差169)增至690 mL(标准差188),平均肥大率为9.5%(标准差10.2)。5例因肥大不足需改用永久性栓塞材料重复栓塞。32例中23例(71.8%)最终完成大范围肝切除,无术后死亡。可吸收栓塞材料行临时PVE可行、安全,并能在大范围肝切除术前诱导有临床意义的肝肥大,支持在部分患者中短暂门静脉闭塞即可刺激肝再生这一设想。EMBORES研究由法国卫生部2015年国家医院临床研究计划资助(Programme Hospitalier de Recherche Clinique National,PHRC-15-15-0201)。
基础研究 (1篇)
Hepatocyte-like cells (HLCs) represent a promising therapeutic approach for acute liver failure (ALF), offering an alternative to primary hepatocytes, which are in short supply. Given the viscoelastic tissue properties of the liver and the growing recognition of the mechanical cues in physiology and disease, we investigated how ALF-induced changes in the liver's mechanical microenvironment might affect HLC-based cell therapy. Here, driven by specific disease-derived mechanical cues, we designed bioinspired hydrogel microspheres with tunable liver viscoelasticity to mimic the mechanical niche of healthy versus ALF liver tissue. We show that a fast-relaxation hydrogel niche mimicking the healthy liver guides the efficient differentiation of human adipose-derived mesenchymal stem cells (hADSCs) into functional HLCs by suppressing the formation of abnormal stress fibers and pathological YAP nuclear translocation through the ROCK axis. In both the carbon tetrachloride-induced and partial hepatectomy-induced ALF mouse models, these mechanically preconditioned HLCs exhibit significant therapeutic efficacy, promoting robust liver regeneration and acting as active mechanical regulators to suppress aberrant host mechanotransduction and remodel the diseased microenvironment. This disease mechanobiology-oriented strategy provides insights into the design of viscoelastic biomaterials for regenerative medicine and demonstrates a promising approach for enhancing cell therapy outcomes in liver failure.
中文摘要:类肝细胞(HLCs)是治疗急性肝衰竭(ALF)的一种有前景的手段,可替代来源紧张的供体原代肝细胞。鉴于肝脏具有黏弹性组织特征,且力学信号在生理与疾病中的作用日益受到重视,我们考察了 ALF 引起的肝脏力学微环境改变对基于 HLC 的细胞治疗可能产生的影响。在此,依据疾病来源的特定力学信号,我们设计了黏弹性可调的仿生水凝胶微球,用以模拟健康肝脏与 ALF 肝组织的力学微环境。结果显示,模拟健康肝脏的快速应力松弛水凝胶微环境可通过 ROCK 轴抑制异常应力纤维形成与病理性 YAP 核转位,从而引导人脂肪间充质干细胞(hADSCs)高效分化为功能性 HLCs。在四氯化碳诱导和部分肝切除诱导的两种 ALF 小鼠模型中,这些经力学预处理的 HLCs 表现出显著的治疗效果,促进肝脏再生,并作为主动的力学调节者抑制宿主异常的力信号转导、重塑病变微环境。这一面向疾病力学生物学的策略为再生医学中黏弹性生物材料的设计提供了思路,也展示了改善肝衰竭细胞治疗结局的一条可行途径。
5肝移植 (2篇)
临床研究 (2篇)
Living liver donation is a major operation performed without direct medical benefit to the donor. Prospective data on longitudinal donor-reported outcomes after minimally invasive donor hepatectomy remain limited, particularly for robotic approaches offered without donor selection. This prospective observational cohort study included all consecutive living liver donors undergoing robotic donor hepatectomy between April 2024 and March 2025. The robotic approach was offered to all donors without preselection. Donors completed the Short Form-36 (SF-36), Body Image Scale (BIS), and Beck Depression Inventory (BDI) questionnaires preoperatively and at 3, 6, and 12 months post-donation. Longitudinal changes relative to baseline were assessed using Wilcoxon signed-rank tests. Associations with donor demographics, perioperative variables, and recipient disease severity were evaluated using Spearman correlation and nonparametric group comparisons. A total of 214 donors were analyzed (mean age 36.4 y, 54% male). Physical Functioning, Role-Physical, Bodily Pain, and General Health declined at 3 months but recovered and returned to baseline by 12 months. Emotional Well-Being and Energy/Fatigue improved beyond baseline by 6 months and remained elevated at 12 months. Body image disturbance and depressive symptoms remained low throughout follow-up. Older donor age was modestly associated with better psychosocial outcomes. Donor complications and early recipient mortality were associated with transient reductions in selected domains without sustained impact. No consistent associations were observed with graft type, donor-recipient relationship, or recipient disease severity. Robotic living donor hepatectomy is associated with excellent physical and psychosocial recovery during the first postoperative year, supporting its donor-centered benefits.
中文摘要:活体肝捐献是一项对捐献者无直接医疗获益的大型手术。微创供肝切除术后纵向供者报告结局的前瞻性数据仍有限,尤其是未对供者进行筛选的机器人入路。这项前瞻性观察性队列研究纳入2024年4月至2025年3月连续接受机器人供肝切除术的所有活体肝捐献者。机器人入路提供给所有捐献者,未作预先筛选。捐献者在术前及捐献后3、6、12个月完成SF-36、体像量表BIS和Beck抑郁量表BDI问卷。相对于基线的纵向变化采用Wilcoxon符号秩检验评估。与供者人口学特征、围手术期变量及受者疾病严重度的关联采用Spearman相关和非参数组间比较评估。共分析214名供者(平均年龄36.4岁,54%男性)。躯体功能、角色-躯体、躯体疼痛和总体健康在3个月时下降,但恢复并在12个月时回到基线。情绪健康与精力/疲劳在6个月时高于基线,并在12个月时仍保持升高。体像困扰和抑郁症状在整个随访期保持较低。供者年龄较大与更好的心理社会结局呈轻度相关。供者并发症和受者早期死亡与部分领域的短暂下降相关,但无持续影响。未观察到与移植物类型、供受者关系或受者疾病严重度的一致关联。机器人活体供肝切除术与术后第一年良好的躯体和心理社会恢复相关,支持其以捐献者为中心的获益。
To determine whether liver transplantation (LT) confers durable oncologic benefit in combined hepatocellular-cholangiocarcinoma (cHCC-CCA) and to identify predictors of recurrence that may guide transplant candidacy. cHCC-CCA is a rare primary liver malignancy with aggressive biological behavior. LT has traditionally been contraindicated due to concerns regarding recurrence. We evaluated long-term outcomes of LT versus liver resection (LR) and compared LT outcomes for cHCC-CCA with those for hepatocellular carcinoma (HCC). Patients with cHCC-CCA who underwent LT or LR between 2010 and 2024 were identified from a prospective database. Survival outcomes, recurrence patterns, and risk factors for recurrence were analyzed. Outcomes of LT for cHCC-CCA were additionally compared with HCC. A total of 79 patients underwent LT (diagnosed on explant) and 32 underwent LR for cHCC-CCA. 5-year overall survival (OS) and recurrence-free survival (RFS) were superior following LT compared with LR (OS: 89.9% vs. 65.6%, P=0.007; RFS: 84.8% vs. 53.1%, P=0.001). This benefit was maintained for tumors within UCSF criteria [overall survival (88.7% LT vs. 65.6% LR, log rank P 0.014) and RFS (89.8% LT vs. 51.6% LR, P<0.001)]. Among LT recipients, OS for cHCC-CCA was comparable to HCC (89.9% vs. 86%, P=0.721). Within the LT cohort, macrovascular invasion (HR 25.01, P=0.003) and poor tumor differentiation (HR 7.29, P=0.004) independently predicted recurrence. In carefully selected patients, cHCC-CCA within UCSF criteria can achieve transplant outcomes comparable to HCC. Macrovascular invasion and poor tumor differentiation are major predictors of recurrence and may inform candidate selection for LT.
中文摘要:评估肝移植(LT)能否为混合型肝细胞癌-胆管癌(cHCC-CCA)带来持久的肿瘤学获益,并寻找可指导移植候选选择的复发预测因素。cHCC-CCA 是一种生物学行为侵袭性强的少见原发性肝脏恶性肿瘤。由于担心复发,肝移植历来被视为禁忌。研究比较肝移植与肝切除(LR)的长期结局,并将 cHCC-CCA 接受肝移植的结局与肝细胞癌(HCC)相比较。从前瞻性数据库中筛选 2010 至 2024 年间接受肝移植或肝切除的 cHCC-CCA 患者,分析生存结局、复发模式及复发危险因素,并将 cHCC-CCA 肝移植结局与 HCC 进行对比。共 79 例因 cHCC-CCA 接受肝移植(经移植肝标本确诊),32 例接受肝切除。肝移植组 5 年总生存(OS)与无复发生存(RFS)均优于肝切除组(OS:89.9% 对 65.6%,P=0.007;RFS:84.8% 对 53.1%,P=0.001)。在符合 UCSF 标准的肿瘤中该获益依然存在(OS:肝移植 88.7% 对肝切除 65.6%,log rank P=0.014;RFS:89.8% 对 51.6%,P<0.001)。肝移植受者中,cHCC-CCA 的 OS 与 HCC 相当(89.9% 对 86%,P=0.721)。在肝移植队列中,大血管侵犯(HR 25.01,P=0.003)与肿瘤低分化(HR 7.29,P=0.004)为复发的独立预测因素。经过严格筛选、符合 UCSF 标准的 cHCC-CCA 患者可获得与 HCC 相当的移植结局。大血管侵犯与肿瘤低分化是复发的主要预测因素,可用于指导肝移植候选者的选择。
6胆道手术 (1篇)
临床研究 (1篇)
Acute cholangitis (AC) is a potentially fatal biliary tract infection most commonly caused by gallstones. While modern-day treatments with antibiotics and biliary decompression have drastically decreased mortality rates, AC still requires prompt intervention. Diagnosis of AC traditionally relied on the presence of the Charcot triad, which has since proven to incompletely capture the complexity of this condition. Modern-day diagnosis, severity grading, and management guidelines provide a more holistic approach. Tokyo Guidelines (TG) are widely used, though newer guidelines, namely the BILE criteria, have recently emerged. These criteria include demonstration of inflammation, cholestasis, and biliary obstruction. Ultrasound is first-line imaging modality with computed tomography or magnetic resonance cholangiopancreatography often used for diagnostic dilemmas. Treatment is dependent on severity, though guidelines generally recommend early decompression (most commonly with endoscopic retrograde cholangiopancreatography [ERCP]) for moderate to severe cases. The optimal timing of biliary drainage remains unclear, with mixed evidence from observational studies and no universal definition of what constitutes "early" vs "urgent" drainage. Laparoscopic cholecystectomy should be performed during index hospitalization, when possible, with multiple studies demonstrating lower morbidity and mortality rates when compared with interval procedures. The prognosis of AC is favorable if treated swiftly and appropriately; in turn, mortality rates increase with severity and delays in diagnosis. AC can be challenging to diagnose and the precise timing of biliary drainage and cholecystectomy is debated. This comprehensive review reflects the most recent evidence and recommendations on severity grading, resuscitation, and timing of ERCP and cholecystectomy to assist clinicians who manage these complex patients.
中文摘要:急性胆管炎(AC)是一种可能致命的胆道感染,最常见由胆石引起。现代抗生素与胆道减压治疗已大幅降低死亡率,但AC仍需及时干预。传统诊断依赖Charcot三联征,但该三联征已被证明不能完整反映疾病复杂性。现代诊断、严重程度分级和管理指南提供了更整体的方法。Tokyo Guidelines(TG)应用广泛,较新的BILE标准近期出现,包括炎症、胆汁淤积和胆道梗阻的证据。超声是一线影像学检查,诊断困难时常用计算机断层扫描或磁共振胰胆管成像。治疗取决于严重程度,指南一般建议中重度病例早期减压,最常用内镜逆行胰胆管造影(ERCP)。胆道引流的最佳时机仍不清楚,观察性研究证据不一,且对「早期」与「紧急」引流缺乏统一定义。条件允许时,腹腔镜胆囊切除术应在本次住院期间完成,多项研究显示与间隔期手术相比,其并发症发生率和死亡率更低。若治疗迅速且适当,AC预后良好;死亡率随严重程度增加和诊断延迟而升高。AC诊断可能困难,胆道引流和胆囊切除术的精确时机仍有争议。该综述汇总严重程度分级、复苏以及ERCP和胆囊切除术时机的最新证据与建议,以帮助临床医生管理这类复杂患者。
7肝转移切除 (1篇)
临床研究 (1篇)
In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whether early relapses (DFS <6 months) are associated with overall survival (OS) benefit. We analyzed individual data of patients with LL-mCRC enrolled in nine randomized trials of first-line chemotherapy plus biologics. Correlation and surrogacy between DFS and psOS were calculated with ρ and R2. psOS of resected patients with DFS <6 months was compared with time from minimum disease load (post-min OS) of unresected patients, with stratification according to baseline tumor burden score (TBS). Time on systemic therapy was also evaluated. Eight hundred fifty-five patients with LL-mCRC were included and 357 (42%) were radically resected. DFS and psOS were highly correlated (ρ = 0.73), with R2 at the patient and trial levels for surrogacy of 0.70 and 0.32, respectively. psOS and post-min OS in resected patients with early relapse (n= 115) and unresected patients (n = 498) were comparable [hazard ratio (HR) 0.88, 95% confidence interval (CI) 0.70-1.11, P = 0.29]. However, a benefit from surgery was detected in patients with high baseline TBS (HR 0.69, 95% CI 0.45-1.05, P = 0.09) but not in patients with low/medium baseline TBS (HR 1.12, 95% CI 0.74-1.69, P = 0.59) (p interaction = 0.10). Resection was associated with a lower percentage of time on systemic therapy (26%) regardless of DFS (47% if <6 months, 26% if ≥6 months) (P < 0.001). In LL-mCRC resected after first-line chemotherapy plus biologics, DFS is highly correlated with psOS, with high patient-level surrogacy. In high-burden patients, liver surgery seems associated with a trend toward long-term benefit, also after early relapse (<6 months), whereas time on systemic therapy is reduced.
中文摘要:在可切除的肝局限性转移性结直肠癌(LL-mCRC)中,异质性回顾性系列发现无病生存期(DFS)与术后总生存期(psOS)仅弱相关,这使DFS作为psOS替代生物标志物的作用受到质疑。早期复发(DFS<6个月)是否与总生存期(OS)获益相关仍不明确。我们分析了九项一线化疗联合生物制剂随机试验中入组的LL-mCRC患者的个体数据。采用ρ和R2计算DFS与psOS之间的相关性和替代性。将DFS<6个月的可切除患者的psOS与不可切除患者自最小疾病负荷起的时间(post-min OS)进行比较,并按基线肿瘤负荷评分(TBS)分层。同时评估全身治疗时间。共纳入855例LL-mCRC患者,357例(42%)接受根治性切除。DFS与psOS高度相关(ρ=0.73),患者水平和试验水平的替代性R2分别为0.70和0.32。早期复发可切除患者(n=115)与不可切除患者(n=498)的psOS和post-min OS相当[风险比(HR)0.88,95%置信区间(CI)0.70-1.11,P=0.29]。然而,在基线TBS高的患者中检测到手术获益(HR 0.69,95% CI 0.45-1.05,P=0.09),而基线TBS低/中等的患者未检测到获益(HR 1.12,95% CI 0.74-1.69,P=0.59)(交互作用P=0.10)。无论DFS如何,切除与全身治疗时间比例较低相关(26%)(DFS<6个月为47%,DFS≥6个月为26%)(P<0.001)。在一线化疗联合生物制剂后切除的LL-mCRC中,DFS与psOS高度相关,患者水平替代性高。在高负荷患者中,肝脏手术似乎与长期获益趋势相关,早期复发(<6个月)后亦然,而全身治疗时间缩短。
8胆管癌 (1篇)
基础研究 (1篇)
Intrahepatic cholangiocarcinoma is a highly lethal malignancy characterized by a rising incidence and a dismal 5-year survival rate of < 10%. While targeted therapies and immunotherapies have expanded treatment paradigms, their clinical efficacy remains hampered by modest patient response rates. Here, we identify total glucosides of paeony and its principal bioactive monomer, paeoniflorigenone (PFG), as potential effective therapeutic agents against ICC, demonstrating potent suppression of malignant phenotypes across multi-dimensional ICC models. Transcriptomic profiling identified ferroptosis as the primary mechanism driving PFG-induced ICC cell death, which is hallmarked by intracellular Fe²⁺ overload, robust ROS generation, and lipid peroxidation. Mechanistically, PFG directly binds to TRIM28, triggering its phosphorylation at Ser824. This modification alleviates repressive H3K9me3 occupancy at the HMOX1 promoter, thereby unlocking local chromatin accessibility to drive HMOX1 transcription and culminate in ferroptosis. Notably, PFG-induced ferroptosis not only curbs ICC cell proliferation and migration but also activates antigen presentation and reshapes a tumoricidal immune microenvironment, characterized by enhanced infiltration and activation of CD8⁺ cytotoxic T cells. In summary, this study unveils a previously unrecognized ferroptosis regulatory pathway-the TRIM28/H3K9me3/HMOX1 axis-and demonstrates that PFG may represent a potential natural small-molecule candidate for ICC treatment.
中文摘要:肝内胆管癌是一种高度致死性恶性肿瘤,发病率上升,5年生存率低于10%。靶向治疗和免疫治疗拓展了治疗模式,但患者应答率有限,临床疗效仍受制约。研究识别出白芍总苷及其主要活性单体芍药内酯酮(PFG)作为针对ICC的潜在有效治疗药物,并在多维ICC模型中显示对恶性表型的有力抑制。转录组分析确定铁死亡是驱动PFG诱导ICC细胞死亡的主要机制,其特征为细胞内Fe²⁺超载、ROS大量生成和脂质过氧化。机制上,PFG直接结合TRIM28,触发其Ser824位点磷酸化。该修饰减轻HMOX1启动子上抑制性H3K9me3占据,提高局部染色质可及性,驱动HMOX1转录并最终导致铁死亡。PFG诱导的铁死亡不仅抑制ICC细胞增殖和迁移,还激活抗原呈递并重塑具有杀肿瘤作用的免疫微环境,表现为CD8⁺细胞毒性T细胞浸润和活化增强。研究揭示此前未被认识的铁死亡调控通路TRIM28/H3K9me3/HMOX1轴,并表明PFG可能是ICC治疗的潜在天然小分子候选药物。
9胰腺癌/胰十二指肠切除 (1篇)
基础研究 (1篇)
Pancreatic ductal adenocarcinoma (PDAC) exhibits profound therapy resistance driven by lysosome-dependent nutrient recycling, metabolic adaptation, and stress tolerance. Current lysosome targeting agents such as chloroquine (CQ)/hydroxychloroquine (HCQ) show limited efficacy due to transient activity and dose-limiting-toxicities. To overcome these limitations, we developed lysostilbenes, a new class of hybrid small molecules combining the CQ pharmacophore with lysosome-disrupting stilbene analogs. Stilbene pharmacophore is the core structural component of resveratrol. Among the synthesized hybrids, lysostilbene-4 emerged as the lead candidate, demonstrating ~30-40-fold greater cytotoxicity against PDAC cells than parent compounds, while sparing nonmalignant cells. At nanomolar concentrations, lysostilbene-4 induced rapid, irreversible lysosomal membrane permeabilization (LMP), initiating a lysosome mitochondria apoptotic cascade via CTSB (cathepsin B) release, BID cleavage, BAX activation, and caspase-mediated apoptosis. In parallel, it abrogated lysosomal recovery by significantly reducing repair, lysophagy, autophagosome maturation, and uncoupling TFEB-driven transcriptional programs from effective lysosome biogenesis. Reduced TFEB mRNA expression correlated with poor overall-survival and disease-free-survival across multiple cancer patients, with a particularly strong association in pancreatic cancer patients. Using TFEB+/+ and TFEB-/- knockout pancreatic cancer cells we establish that lysostilbene-4 exerts severe cytotoxicity by inducing persistent lysosomal-damage and disrupting autophagosome-lysosome assembly, with vulnerability further amplified in TFEB-deficient cells. This finding underscores TFEB as a key determinant of lysosomal-resilience and a potential predictive biomarker. Importantly, lysostilbene-4 was well tolerated in preclinical mouse-models at supra-therapeutic doses without systemic-toxicity. These findings position lysostilbene-4 as a first-in-class lysosome-targeting therapeutic that enforces sustained lysosomal collapse while compromising adaptive recovery-mechanisms, providing a mechanistically precise and safe strategy against PDAC.Abbreviations: ALG: autophagy-lysosome genes; AMPK: AMP-activated protein kinase; CASM: conjugation of ATG8s to single membranes; CTSB: cathepsin B; LGALS3: galectin 3; LMP: lysosomal membrane permeabilization; LS: lysostilbene; MTOR: mechanistic target of rapamycin kinase; PDAC: pancreatic ductal adenocarcinoma; TCGA: The Cancer Genome Atlas; TFEB: transcription factor EB; ULK1: unc-51 like autophagy activating kinase 1.
中文摘要:胰腺导管腺癌(PDAC)因依赖溶酶体进行营养回收、代谢适应和应激耐受而表现出显著治疗抵抗。现有氯喹(CQ)/羟氯喹(HCQ)等溶酶体靶向药物因作用短暂和剂量限制性毒性而疗效有限。为克服这些限制,我们开发了lysostilbenes,这是一类将CQ药效团与破坏溶酶体的二苯乙烯类似物结合的新型杂合小分子。二苯乙烯药效团是白藜芦醇的核心结构组分。在合成的杂合分子中,lysostilbene-4成为先导候选物,对PDAC细胞的细胞毒性比母体化合物高约30-40倍,同时不伤害非恶性细胞。在纳摩尔浓度下,lysostilbene-4快速诱导不可逆的溶酶体膜通透化(LMP),通过CTSB(组织蛋白酶B)释放、BID剪切、BAX激活和caspase介导的凋亡启动溶酶体-线粒体凋亡级联。同时,它通过显著降低修复、溶酶体自噬、自噬体成熟,并使TFEB驱动转录程序与有效溶酶体生成解耦联,阻断溶酶体恢复。TFEB mRNA表达降低与多癌种患者较差的总生存和无病生存相关,在胰腺癌患者中关联尤其强。使用TFEB+/+与TFEB-/-敲除胰腺癌细胞,我们确定lysostilbene-4通过诱导持续溶酶体损伤和破坏自噬体-溶酶体组装发挥严重细胞毒性,TFEB缺陷细胞的脆弱性进一步放大。这一发现强调TFEB是溶酶体韧性的关键决定因素和潜在预测生物标志物。重要的是,lysostilbene-4在临床前小鼠模型中于超治疗剂量下耐受良好,无全身毒性。这些发现使lysostilbene-4成为首创类溶酶体靶向治疗药物,可强制持续溶酶体崩溃并削弱适应性恢复机制,为PDAC提供机制精确且安全的策略。缩写:ALG:自噬-溶酶体基因;AMPK:AMP活化蛋白激酶;CASM:ATG8s与单膜缀合;CTSB:组织蛋白酶B;LGALS3:半乳糖凝集素3;LMP:溶酶体膜通透化;LS:lysostilbene;MTOR:雷帕霉素激酶机制靶点;PDAC:胰腺导管腺癌;TCGA:癌症基因组图谱;TFEB:转录因子EB;ULK1:unc-51样自噬激活激酶1。
10肝癌手术 (1篇)
临床研究 (1篇)
Very early recurrence (within 1 year after resection) of hepatocellular carcinoma (HCC) indicates aggressive tumor biology and poor prognosis; however, non-invasive prediction tools remain scarce. This study aimed to develop and validate MRI-based models for predicting very early recurrence and to explore their biological underpinnings. This international, multicenter cohort study retrospectively included 1,811 consecutive patients who underwent curative-intent resection for a single BCLC 0/A HCC and preoperative contrast-enhanced MRI or CT at 14 tertiary care hospitals in China, South Korea, Singapore, France, and the USA, as well as 40 eligible patients from the TCGA-LIHC dataset. To predict 1-year recurrence-free survival (RFS), MRI for Very Early Recurrence Prediction (MERP) models were developed using either preoperative variables alone (MERP-pre) or a combination of pre- and postoperative variables (MERP-post) in the derivation cohort (n = 628). The models were externally validated in Eastern (n = 775) and Western (n = 178) test cohorts and further evaluated in a CT test cohort (n = 230). Biological correlates were investigated using whole-exome and RNA sequencing. MERP-pre incorporated alpha-fetoprotein, tumor size, portal venous phase peritumoral hypoenhancement, and intratumoral blood products, whereas MERP-post replaced tumor size with microvascular invasion (MVI). Both models outperformed major staging systems and the IMbrave050 criteria across all test cohorts (C-index, 0.685-0.790 vs. 0.524-0.682; p values, <0.001 to 0.046) and improved risk reclassification (net reclassification improvement [NRI], 0.004-0.372). The MERP models consistently stratified patients into high- and low-risk groups with distinct 1-year RFS rates (all p <0.001). MERP-pre further improved MVI-based risk reclassification (NRI, 0.323) and survival risk stratification. Tumors classified as low risk by MERP-pre exhibited features of the non-proliferative class, increased lipid catabolism, and an immunoactive microenvironment. The MERP models may serve as robust, generalizable, and biologically informed tools for predicting very early HCC recurrence and may help refine risk-stratified management strategies. Very early recurrence (VER) of hepatocellular carcinoma (HCC) within 1 year after resection reflects aggressive tumor biology and is associated with poor prognosis, yet reliable tools for predicting VER remain scarce. In this large, international, multicenter cohort of patients with a single Barcelona Clinic Liver Cancer stage 0/A HCC undergoing curative-intent resection, we developed and externally validated two MRI-based models (MERP-pre and MERP-post) that integrate routinely available clinicopathological and imaging variables. The MERP models consistently outperformed existing prognostic systems and effectively stratified patients into high- and low-risk groups with distinct 1-year recurrence-free survival across diverse cohorts. These findings highlight the potential of the MERP models to complement existing prognostic systems and optimize risk-stratified management of HCC.
中文摘要:肝细胞癌(HCC)切除术后1年内的极早期复发提示肿瘤生物学行为侵袭性强、预后差,但无创预测工具仍缺乏。本研究旨在建立并验证基于MRI的极早期复发预测模型,并探讨其生物学基础。这项国际多中心队列研究回顾性纳入中国、韩国、新加坡、法国和美国14家三级医院连续收治的1811例接受根治性切除术的单发BCLC 0/A期HCC患者,这些患者术前接受增强MRI或CT检查;同时纳入TCGA-LIHC数据集中40例符合条件的患者。为预测1年无复发生存(RFS),在推导队列(n=628)中分别使用仅术前变量(MERP-pre)或术前与术后变量联合(MERP-post)建立MRI极早期复发预测(MERP)模型。模型在东方(n=775)和西方(n=178)外部测试队列中验证,并在CT测试队列(n=230)中进一步评估。通过全外显子组和RNA测序探讨生物学相关因素。MERP-pre纳入甲胎蛋白、肿瘤大小、门静脉期瘤周低强化和瘤内血液产物,MERP-post则以微血管侵犯(MVI)替代肿瘤大小。两个模型在所有测试队列中均优于主要分期系统和IMbrave050标准(C指数0.685~0.790对0.524~0.682;p值<0.001至0.046),并改善风险重分类(净重分类改善[NRI]0.004~0.372)。MERP模型持续将患者分为高风险和低风险组,两组1年RFS率不同(均p<0.001)。MERP-pre进一步改善基于MVI的风险重分类(NRI 0.323)和生存风险分层。MERP-pre判为低风险的肿瘤表现出非增殖类特征、脂质分解代谢增强及免疫活跃微环境。MERP模型可作为稳健、可推广且具生物学依据的工具,用于预测HCC极早期复发,并可能帮助细化风险分层管理策略。HCC切除术后1年内的极早期复发(VER)反映肿瘤生物学行为侵袭性强,并与预后差相关,但可靠的VER预测工具仍缺乏。在这项大型国际多中心队列中,单发巴塞罗那临床肝癌0/A期HCC患者接受根治性切除术,我们建立并外部验证了两个基于MRI的模型(MERP-pre和MERP-post),整合常规可获得的临床病理和影像变量。MERP模型在不同队列中持续优于现有预后系统,并有效将患者分为1年无复发生存不同的高风险和低风险组。这些发现提示MERP模型有潜力补充现有预后系统,优化HCC风险分层管理。